CoChat

Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis

Masson, Walter, Lobo, Martín, Nogueira, Juan P., Barbagelata, Leandro, Touzas, Pedro, Frías, Juan P. · 2026 · Reviews in Endocrine and Metabolic Disorders

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown significant metabolic benefits and weight reduction, but its anti-inflammatory effects have been less studied. This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6). A random-effects model was used. Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis). Compared to placebo, tirzepatide reduced hsCRP (mean difference [MD]: -32.9; 95% confidence interval [CI]: -33.6 to - 32.2; I²=15.3%) and IL-6 (MD: -17.8; 95% CI: -24.3 to - 11.3; I² = 1.6%). Levels of hsCRP were significantly reduced with tirzepatide at 15 mg (MD: -32.9; 95% CI: -33.6 to - 32.2; I²=4.4%), 10 mg (MD: -33.9; 95% CI: -50.3 to - 17.6; I²=41.8%), and 5 mg (MD: -20.3; 95% CI: -35.2 to - 5.3; I²=0%). Similarly, IL-6 levels were significantly reduced with tirzepatide at 5 mg (MD: -18.8; 95% CI: -32.9 to - 4.6; I²=17.2%), 10 mg (MD: -17.9; 95% CI: -28.2 to - 7.7; I²=2.1%), and 15 mg (MD: -16.8; 95% CI: -31.1 to - 2.6; I²=47.4%). This study demonstrated that tirzepatide use is associated with a significant reduction in inflammatory markers, regardless of the population studied or treatment regimen.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11154-025-09991-4

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Cited by

See all 21

Metadata

Authors
Masson, W., Lobo, M., Nogueira, J. P., Barbagelata, L., Touzas, P., & Frías, J. P.
Affiliations
  • Hospital Italiano de Buenos Aires (AR)
  • Universidad Internacional de las Américas (CR)
  • Charles R. Drew University of Medicine and Science (US)
Corresponding author
Masson, Walter
Venue
Reviews in Endocrine and Metabolic Disorders
Published
2025-10-01
Volume
27
Issue
1
Pages
5-15
ISSN
  • 1389-9155 (ISSN-L)
  • 1573-2606
OpenAlex
W4414685749
Cited by
21
References
50
Citations by year
2026: 20 · 2025: 1
FWCI
3.20
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Reviews in Endocrine and Metabolic Disorders (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, anti-inflammatory activity, high-sensitivity C-reactive protein, interleukin-6, GIP/GLP-1 receptor agonist, inflammatory markers, weight loss, obesity
MeSH terms
Tirzepatide, Anti-Inflammatory Agents, C-Reactive Protein, Gastric Inhibitory Polypeptide, Humans, Inflammation, Interleukin-6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1007/s11154-025-09991-4
The paper
Masson, W., Lobo, M., Nogueira, J. P., Barbagelata, L., Touzas, P., & Frías, J. P. (2026). Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-025-09991-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.